Maayan Shemer, Michal Shimonovitz, Rozalin Furer, Adam Abu-Abeid, Danit Dayan, Schlomo Schneebaum, Mor Miodovnik, Eran Nizri
The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm). Data on the rate and pattern of recurrence after a negative sentinel lymph node biopsy (SLNB) are sparse. We retrospectively searched our institutional database and retrieved the records of patients with thin melanomas who underwent an SLNB with negative results. We analyzed patterns of recurrence, time to recurrence, and mode of diagnosis. Thirteen of the 198 patients with thin melanomas and negative SLNB results had tumor recurrence (6...
June 14, 2024: Melanoma Research
Prisca Bustamante, Jacqueline Coblentz, Christina Mastromonaco, Emma Youhnovska, Hiroaki Ito, Rita Pinto Proença, Cristina Fonseca, Kyle Dickinson, Emily Marcotte, Myriam MacDonald, Ana-Beatriz Toledo-Dias, Sabrina Bergeron, Alicia Goyeneche, Rafaella Atherino Schmidt Andujar, Thupten Tsering, Alexander Laskaris, Eva Jin, Amélie Nadeau, Tiffany Porraccio, Miguel N Burnier, Julia V Burnier
Uveal melanoma is the most common intraocular tumor in adults. Our group has previously developed a human uveal melanoma animal model; however, adverse effects caused by the immunosuppressive agent, cyclosporine A, prevented animals from surviving more than 12 weeks. In this study, we tested multiple cyclosporine A doses over an extended disease course up to 20 weeks, providing complete clinical imaging of intraocular tumors, histopathological analysis and liquid biopsy biomarker analysis. Twenty albino rabbits were divided into four groups with different daily cyclosporine A schedules (0-10 mg/kg) and inoculated with human uveal melanoma cell lines, 92...
June 7, 2024: Melanoma Research
Huasheng Liu, Hong Jiang, Qianqian Shan
This meta-analysis aimed to evaluate the comparative diagnostic performance of reflectance confocal microscopy (RCM) and dermoscopy in detecting cutaneous melanoma patients. An extensive search was conducted in the PubMed and Embase databases to identify available publications up to December 2023. Studies were included if they evaluated the diagnostic performance of RCM and dermoscopy in patients with cutaneous melanoma. The quality of the included studies was assessed using the Quality Assessment of Diagnostic Performance Studies (QUADAS-2) tool...
June 7, 2024: Melanoma Research
Pan Luo, Rui Guo, Dejin Gao, Qingguo Zhang
OBJECTIVE: This study aimed to elucidate the genetic aspects of the relationship between sex hormones and cutaneous melanoma risk, providing valuable insights into this complex association. METHODS: In this study, we used estradiol, bioavailable testosterone, sex hormone-binding globulin, and total testosterone as the exposure and melanoma as the outcome for two-sample Mendelian randomization analysis. In this study, a random-effects inverse-variance weighting (IVW) model was used as the main analysis model, and the corresponding weighted median, simple mode, weighted mode, and Mendelian randomization‒Egger methods were used as supplementary methods...
June 5, 2024: Melanoma Research
Federica Dini, Pietro Susini, Biancamaria Zuccaro, Giuseppe Nisi, Roberto Cuomo, Luca Grimaldi, Gabriella Perillo, Luca Tinunin, Pietro Antonini, Alessandro Innocenti, Giovanni Cecchi, Elisabetta Gambale, Laura Doni, Cinzia Mazzini, Nicola Santoro, Vincenzo De Giorgi
Eyelid melanoma (EM) is a malignant neoplasm accounting for around 1% of eyelid malignancies. Because of its rarity, most of our knowledge of EM is currently based on studies of cutaneous melanomas located elsewhere. Accordingly, this study aimed to specifically evaluate EM characteristics, management strategies, and prognosis. A retrospective study was carried out on patients diagnosed with EM at Careggi University Hospital, Florence between May 2012 and May 2022. In addition, a systematic review of relevant literature was conducted, encompassing studies published from 2013 to 2023...
June 3, 2024: Melanoma Research
Wolfram Samlowski, Michelle A Silver, Andriana Hohlbauch, Shujing Zhang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Yunfei Wang, Ila Sruti, Ruixuan Jiang
Long follow-up time is needed for overall survival (OS) data to mature for early-stage melanoma. This retrospective study aimed to describe the relationships between OS and two intermediate endpoints - real-world recurrence-free survival (rwRFS) and real-world distant metastasis-free survival (rwDMFS) - for patients with stage IIB or IIC melanoma that was completely resected from 1 January 2008 to 31 December 2017, with follow-up to 31 December 2020. We used three different approaches to describe the relationships: estimates of correlation using Kendall τ rank correlation; comparisons of all-cause survival with/without recurrence or distant metastasis using adjusted Cox proportional hazard models; and landmark analyses of all-cause survival stratified by recurrence status at 1-5 years...
May 27, 2024: Melanoma Research
An-Sofie Vander Mijnsbrugge, J Cerckel, I Dirven, J Tijtgat, M Vounckx, N Claes, Bart Neyns
Melanoma patients failing all approved treatment options have a poor prognosis. The antimelanoma activity of regorafenib (REGO), a multitargeted kinase inhibitor, has not been investigated in this patient population. The objective response rate and safety of REGO treatment in advanced melanoma patients was investigated retrospectively. Twenty-seven patients received REGO treatment. All patients had progressed on anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint inhibition and BRAF/MEK inhibitors (in case of a BRAF V600mutation)...
May 27, 2024: Melanoma Research
Alice Indini, Rossana Gueli, Michele Cerati, Erika Rijavec, Marco Parravicini, Sabrina Casagrande, Cristina Rovelli, Paolo Antonio Grossi, Francesco Grossi
Immunotherapy has improvedsurvival outcomes of patients with advanced melanoma. Lower gastrointestinal tract immune-related adverse events (irAEs) are common during treatment; however, gastritis is not frequently observed. Herein, we report a case of severe cytomegalovirus (CMV)-related gastritis in a patient treated with ipilimumab and nivolumab for metastatic melanoma. This report presents a 60-year-old woman with stage IV BRAF wild-type melanoma. t. After the second course of ipilimumab-nivolumab, the patient reported epigastric discomfort after meals, anorexia, and subsequent nausea, vomiting, epigastric pain, and weight loss...
May 20, 2024: Melanoma Research
Mark R Albertini, Cindy L Zuleger, Erik A Ranheim, Oyewale Shiyanbola, Paul M Sondel, Zachary S Morris, Jens Eickhoff, Michael A Newton, Irene M Ong, Rene Welch Schwartz, Rubi Hayim, Ilene D Kurzman, Michelle Turek, David M Vail
Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it is similar to human melanoma and expresses GD2. The objectives of this study were to evaluate safety, radiation fractionation, and identify informative biomarkers of an in-situ tumor vaccine involving local radiation therapy plus intratumoral-immunocytokine in melanoma tumor-bearing dogs. Twelve dogs (six dogs/arm) with locally advanced or metastatic melanoma were randomized to receive a single 8 Gy fraction (arm A) or three 8 Gy fractions over 1 week (arm B) to the primary site and regional lymph nodes (when clinically involved) with the single or last fraction 5 days before intratumoral-immunocytokine at 12 mg/m2 on 3 consecutive days...
May 20, 2024: Melanoma Research
Ahmet Anil Ozluk, Damla Gunenc, Saadet Sim Yildirim, Burcak Karaca
With the widespread use of immune checkpoint inhibitors, management of immune-related adverse effects specific to these treatments became an important research era in patient management. Among these, immune-related hepatotoxicity (IRH) is an adverse event that can be fatal. While the first-line treatment of IRH is well established, there is still no consensus regarding the management approach for steroid-refractory, severe IRH. Here, we report four patients with metastatic melanoma who developed IRH during antiprogrammed cell death protein-1 plus anticytotoxic T-lymphocyte-associated protein-4 combination therapy and review of the literature...
April 29, 2024: Melanoma Research
Yao Gao, Yao Wang, Yueyue Luo, Yong Zhang, Saiqi Wang, Xiance Tang, Peng Qin, Benling Xu, Quanli Gao, Tiepeng Li
The aim of this study is to determine whether the pretreatment CD8+PD-1+ to CD4+PD-1+ (PERLS) ratio is an independent risk prognostic factor of advanced melanoma patients. We retrospectively analyzed the efficacy and flow cytometry data from advanced melanoma patients who received PD-1 inhibitor as monotherapy between January 1, 2018 and January 26, 2022. Fifty-nine patients were enrolled, the PERLS cutoff was 1.125. PERLS did not correlate with clinical characteristics but were significantly associated with baseline CD8+, CD4+, and CD8+PD-1+ T cells...
April 22, 2024: Melanoma Research
Lawrence W Wu, Jacqueline J Tao, Diana McDonnell, Benjamin Izar
Pseudoprogression encapsulates a process of temporary radiographic growth followed by subsequent regression of metastatic melanoma lesions in response to immune checkpoint blockade (ICB), such as the combination of anti-programmed cell death protein 1 (PD-1) and anticytotoxic T-lymphocyte-associated antigen 4 therapy. This occurs in approximately 5-10% of ICB-treated patients, but has not yet been described in the context of novel combination therapies. Here, we report a case of an 89-year-old patient with metastatic melanoma to the liver, lung and lymph nodes, who underwent treatment with Opdualag (combining anti-PD-1 nivolumab and anti-lymphocyte-activation gene 3 relatlimab ICBs), and developed pseudoprogression after two cycles of therapy...
April 18, 2024: Melanoma Research
Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin
Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK). However, they should be careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension...
April 5, 2024: Melanoma Research
D Suwajanakorn, A M Lane, A K Go, C D Hartley, M Oxenreiter, F Wu, E S Gragoudas, R J Sullivan, K Montazeri, I K Kim
Surveillance frequency for metastasis is guided by gene expression profiling (GEP). This study evaluated the effect of GEP on time to diagnosis of metastasis, subsequent treatment and survival. A retrospective study was conducted of 110 uveal melanoma patients with GEP (DecisionDx-UM, Castle Biosciences, Friendswood, Texas, USA) and 110 American Joint Committee on Cancer-matched controls. Surveillance testing and treatment for metastasis were compared between the two groups and by GEP class. Rates of metastasis, overall survival and melanoma-related mortality were calculated using Kaplan-Meier estimates...
April 5, 2024: Melanoma Research
Vincenzo Maione, Martina Perantoni, Luca Bettolini, Stefano Bighetti, Mariachiara Arisi, Cesare Tomasi, Paolo Incardona, Piergiacomo Calzavara-Pinton
This case-control study seeks to investigate the influence of histological findings, specifically regression, its extent and tumor-infiltrating lymphocyte (TILs), on result of sentinel lymph node (SLN) biopsy, 5-year melanoma-specific survival (MSS), and relapse-free survival (RFS). We included all patients with cutaneous melanoma who underwent SLN biopsy at the Melanoma Center of the University of Brescia, following the Italian Association of Medical Oncology National guidelines from January 2008 to August 2018...
April 2, 2024: Melanoma Research
Nilesh Kodali, Abhijit Bhattaru, Isabella Blanchard, Yash Sharma, Shari R Lipner
The incidence and prevalence of melanoma are increasing globally, presenting a significant public health concern. The main genetic drivers of melanoma include BRAF, NRAS, KIT and triple wild-type (TWT) mutations. Little is known about the effects of these mutations on outcomes in terms of demographics and patient characteristics. We examined differences in melanoma mortality risk and mutation count across mutation type and patient disease profile. We extrapolated primary melanoma patient data from 14 studies via the cBioportal database...
March 29, 2024: Melanoma Research
Marie Fabre, Anouck Lamoureux, Laurent Meunier, Quentin Samaran, Candice Lesage, Céline Girard, Aurélie Du Thanh, Lionel Moulis, Olivier Dereure
Although current systemic therapies significantly improved the outcome of advanced melanoma, the prognosis of patient with central nervous system (CNS) metastases remains poor especially when clinically symptomatic. We aimed to investigate the efficiency of CNS targets and tolerance of second-line combined anti-PD1/dual-targeted anti-BRAF/anti-MEK therapy implemented in patients with CNS progression after initially efficient first-line combined targeted therapy in patients with BRAF-mutated melanoma in a real-life setting...
March 28, 2024: Melanoma Research
Hemali Shah, Rose Parisi, Emily Everdell, Paul Feustel, Lindy Davis
No abstract text is available yet for this article.
June 1, 2024: Melanoma Research
Sri Siddharth Nekkanti, Syed Nusrath, Rajesh Jarang, Basanth Kumar Rayani, Yerramshetty Vamshi Krishna, Kalidindi Venkata Vijaya Narsimha Raju
Melanoma is known for its high metastatic potential and aggressive growth. Recurrence is common post-surgery, sometimes leading to unresectable disease. Locally recurrent unresectable melanoma of extremity has been treated with high-dose anticancer chemotherapy via isolated limb perfusion (ILP) to improve local efficacy of drug and salvage limbs. Standard ILP monitoring uses radiolabeled dyes, requiring specialized personnel and involving radiation exposure. In this case, we used indocyanine green (ICG) to track systemic drug leakage during ILP...
March 15, 2024: Melanoma Research
Marie Leroy, Eve Desmedt, Laure Deramoudt, Michèle Vasseur, Pascal Odou, Hélène Béhal, Bertrand Décaudin, Laurent Mortier, Nicolas Simon
Nivolumab was first authorized at a weight-based dose (WBD) of 3 mg/kg every two weeks (Q2W). Since 2017, a fixed dose (FD) regimen [first 240 mg Q2W and then 480 mg per month (Q4W)] was allowed. The objective of the study was to compare a WBD regimen and an FD regimen with regard to effectiveness and safety. We conducted a single-center, retrospective, real-life study of consecutive adult patients who had received a WBD of nivolumab or an FD of 480 mg Q4W. The primary endpoint was the occurrence of grade ≥3 immune-related adverse events (irAEs)...
March 15, 2024: Melanoma Research
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.